Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins

Abstract

Low chemotherapy response in PCa could be explained, in part, by over-expression of functional MDR proteins. Expression and function of these proteins should be evaluated to enhance efficacy of docetaxel-based therapies of patients with hormone-resistant PCa.

Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers

“…So far, more than 140 ABC transporters have been identified [13,14] and 49 of them have been encountered in human, including P-glycoprotein (P-gp, ABCB1) and the multidrug resistance-associated protein 1 (MRP1, ABCC1) [15]. Over-expression of P-gp and MRP1 has been implicated in the MDR of breast, prostate and bladder cancers, leading to low survival rates and poor patient prognoses [16][17][18][19][20][21][22]. Although P-gp and MRP1 are highly expressed in bronchial epithelia [23], their roles in the MDR of NSCLC and their potential as therapeutic targets of this disease have so far not been fully elucidated.…”

Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis

“…The presence of a side population has been also reported in PCa cells (Pascal et al 2007). Interestingly, ABC transporters are thought to be responsible for drug resistance in most cancers (Sharom 2008;Stavrovskaya andStromskaya 2008), including PCa (Sánchez et al 2009;Sánchez et al 2011).…”

Relationship between multidrug resistance 1 polymorphisms and the risk of prostate cancer in Chinese populations

“…Previous studies have demonstrated that MDR1 is an important candidate gene in the pathogenesis of osteoporosis (van Brussel and Mickisch, 2003;Sanchez et al, 2009;Sanchez et al, 2011). To the best of our knowledge, the current study is the first to investigate the prevalence of the c.1465C>T variant, which is located in exon14 of MDR1, and evaluate its relationship with Pca risk.…”

“…The pathogenesis of Pca is still largely unknown, with genetic and environmental factors likely contributing to increased risk of the disease (Pienta and Esper 1993;Lichtenstein et al, 2000;Schaid, 2004). Several candidate genes have been suggested to be associated with Pca, including multidrug resistance 1 (MDR1) (van Brussel and Mickisch, 2003;Sanchez et al, 2009;Sanchez et al, 2011), X-ray repair complementing group 1 (Hirata et al, 2007;Agalliu et al, 2010;Dhillon et al, 2011;Kuasne et al, 2011;Langsenlehner et al, 2011), xeroderma pigmentosum group D gene (Mandal et al, 2010), APEX nuclease 1 gene (Agalliu et al, 2010;Kuasne et al, 2011;Mittal et al, 2012), Toll-like receptor 4 (Jing et al, 2012), axis inhibition protein 2 (Pinarbasi et al, 2011), 2-5A-dependent RNase (Wei et al, 2012), complementation group G gene (Berhane et al, 2012), and N-acetyltransferase types 1 (Gong et al, 2011) and 2 (Gong et al, 2011;de Lima Junior et al, 2012). MDR1 is an important candidate gene for Pca.…”

“…MDR1 is an important candidate gene for Pca. Evidence from previous studies has suggested that common polymorphisms in MDR1 are associated with the risk of Pca (van Brussel and Mickisch, 2003;Sanchez et al, 2009;Sanchez et al, 2011). Several MDR1 singlenucleotide polymorphisms (SNPs) such as C2677T and C3435T have been detected to affect the risk of Pca (Narter et al, 2006).…”